The study found that homologous recombination repair mutant type (HRRmt) was prognostic of progression-free survival and predictive for olaparib activity in women with recurrent platinum-sensitive ovarian cancer. Patients with BRCA mutations showed clinically significant activity when treated with experimental drugs.
The NRG-GOG 0281/LOGS trial demonstrated that trametinib significantly reduces disease progression and improves response rates in women with recurrent low-grade serous carcinoma of the ovary/peritoneum. The study found a trend towards higher overall survival rates when compared to standard of care options.
The NRG-RTOG 1010 clinical trial found that adding trastuzumab to chemoradiation and surgery did not improve disease-free survival for HER2-positive esophageal adenocarcinoma patients. Despite this, the study highlights future research opportunities to explore combining trastuzumab with other HER2-targeting agents.
The NRG Oncology GOG 0261 trial demonstrated that paclitaxel and carboplatin is a non-inferior alternative to paclitaxel and ifosfamide for treating women with uterine carcinosarcoma. This regimen offers improved progression-free survival and overall survival compared to the current standard of care.
A new NRG Oncology clinical trial found that bupropion did not improve sexual desire in female cancer survivors. The trial evaluated the effects of extended-release bupropion on postmenopausal women with low baseline sexual desire scores.
The NRG-RTOG 0815 trial found that adding androgen suppression to dose-escalated radiotherapy did not improve overall survival, but reduced rates of biochemical failure and distant metastases. Future studies are needed to identify subsets of patients who may benefit from this intervention.
A Phase III clinical trial found no significant increase in genitourinary or gastrointestinal toxicity with hypofractionated post-operative prostate bed radiotherapy compared to conventional radiotherapy. However, dose-escalated radiation therapy was not shown to be superior to conventional RT.
A long-term analysis of NRG-RTOG 9804 shows breast radiation following lumpectomy significantly reduces the incidence of ipsilateral breast recurrence (IBR) for 'low risk' ductal carcinoma in situ (DCIS). The study found a significant reduction in IBR with radiation, with lower rates observed at 10 and 15 years compared to observation.
In the NRG-LU001 clinical trial, adding metformin to concurrent chemoradiation did not improve one-year progression-free survival (PFS) in patients with locally advanced non-small cell lung cancer. The study found nearly identical overall survival rates between the two groups.
The NRG-BR001 trial found SBRT to be safe for patients with multiple metastases, with no dose-limiting toxicities and over 50% of participants alive at 2 years. The study used extensive radiation QA processes and was the first to require 3D image guidance during treatment.
A combination of reduced-dose radiotherapy using IMRT combined with concurrent cisplatin met the threshold for disease control and quality of life in good-risk patients with HPV-associated oropharyngeal squamous cell carcinoma. This approach yields improved outcomes compared to standard treatment, with lower rates of acute toxicities.
The NRG Oncology trial shows improved in-field tumor control with adaptive radiotherapy, increasing local-regional tumor control by 11% and primary tumor control by 17%. The study's results suggest individualizing radiotherapy dose prescriptions according to patient's intrinsic sensitivity for better survival outcomes.
The NRG Oncology phase II clinical trial determined that the combination of total neoadjuvant therapy with pembrolizumab and chemoradiotherapy is safe for patients with locally-advanced rectal cancer (LARC). However, it may not offer any statistically significant improvement in downstaging of the cancer at the time of surgery.
The study found that 5-year freedom from biochemical failure stands at 68%, comparable to other salvage modalities. At 10 years, the rate dropped to 54%. Late Grade 3 gastrointestinal and genitourinary adverse events occurred in 14% of participants.
The study found that patients with a radio-sensitive genotype have better survival with standard radiation therapy, while those with the resistant genotype fare better with high dose radiotherapy. High dose radiotherapy is associated with shorter survival times among patients with the sensitive genotype.
The NRG-RTOG 0712 trial demonstrated high efficacy rates for both gemcitabine and daily radiation regimens, with 79% and 85% distant metastasis-free rates at 3 years, respectively. The findings confirm the acceptance of these treatments as alternatives to cystectomy.
The study found that MFS was strongly correlated with OS (τ = 0.86), while BF and DM were only moderately and weakly correlated with OS, respectively. The analysis suggests that researchers should be cautious when inferring clinical benefit from studies using biochemical failure as a surrogate for overall survival.
A phase II trial found no statistically significant overall survival differences between dose-intensification radiation therapy (IMRT) and standard-dose radiation therapy with temozolomide treatments. However, MGMT methylation and RPA were predictive of progression-free survival.
A clinical trial found that patients with IDH-mutant high-risk LGG, regardless of codeletion status, receive a survival benefit from adding postradiation chemotherapy. The study supports the use of WHO-defined molecular subgroups in predicting response to treatment.
The NRG Oncology trial NSABP B-43 found a statistically non-significant, modest reduction in the rate of recurrence among women that received trastuzumab. The study showed an annual IBTR event rate of 0.80% per year in the RT+T group compared to 0.99% per year in the RT group.
A phase III clinical trial found that the addition of cediranib to olaparib and standard platinum-based chemotherapy did not improve progression-free survival outcomes, but showed similar activity in patients. The study suggests potential for non-platinum based alternatives in certain biomarker subgroups.
The NRG Oncology trial RTOG 1010 found that adding trastuzumab to neoadjuvant trimodality treatment did not improve disease-free survival for patients with HER2-positive local and locally advanced esophageal adenocarcinoma. The study also showed no significant differences in treatment-related toxicity between the two arms.
The NRG-CC001 trial found that lowering radiotherapy dose to hippocampal stem cells reduces cognitive toxicity and neurologic symptoms in patients with brain metastases. Patients who received whole-brain radiotherapy with hippocampal avoidance reported improved cognitive function, reduced fatigue, and fewer cognitive symptoms.
The study found that higher doses of radiation and adding the drug cetuximab did not improve patient survival compared to standard of care chemoradiation. The 5-year overall survival estimate for the standard radiation dose arm was 32.1%, amongst the highest for Stage III NSCLC.
A recent NRG Oncology study found that breast-conserving treatment without surgery is not feasible based on the study's criteria. The study showed a negative predictive value of 77.5% for tumor bed biopsies, which falls short of the required threshold to support omitting surgery.
The NRG Oncology/NSABP B-42 trial found that extending letrozole therapy for five additional years improved disease-free survival in postmenopausal women with HR+ breast cancer. The study showed a 26% decrease in the risk of breast-cancer-free interval events and a 29% reduction in distant recurrence rates.
The NRG Oncology clinical trial found that accelerated partial-breast irradiation (APBI) did not meet the criteria for equivalence to whole-breast irradiation (WBI) in controlling ipsilateral breast tumor recurrence. APBI did show a 1% difference in 10-year cumulative incidence of IBTR compared to WBI.
Results from NRG-GOG 9929 show that ipilimumab is tolerated in the curative treatment of women with lymph node-positive cervical cancer. The trial found a 12-month progression-free survival rate of 81% and overall survival rate of 90%. Future studies are needed to identify therapeutic targets for improved outcomes.
A secondary analysis of the NRG Oncology clinical trial shows that neurocognitive function (NCF) declines in half of patients with high-risk, low-grade gliomas up to a year after receiving temozolomide-based chemoradiotherapy. However, quality of life (QOL) remains stable or improves in these patients, according to the study.
A new trial shows that breast cancer patients who experience a local recurrence in the same breast after lumpectomy and radiation can benefit from partial-breast re-irradiation as an alternative to mastectomy. The treatment targets the affected area with high-dose radiation, reducing exposure to surrounding tissue.
A secondary analysis of NRG-RTOG 9601 showed that pre-SRT PSA was a prognostic and predictive biomarker in determining the benefit of adding anti-androgen therapy to early SRT. Patients with PSAs <0.6 ng/mL experienced an increase in other-cause mortality and higher-grade cardiac events.
The NRG-HN002 trial found that reduced-dose intensity-modulated radiotherapy (IMRT) with cisplatin achieved acceptable progression-free survival (PFS) rates and swallowing-related quality of life for p16-positive oropharyngeal cancer patients. Patients who received IMRT and cisplatin reported higher acute toxicities, but similar late t...
A substudy of the NRG Oncology clinical trial found that women rated post-lumpectomy partial breast irradiation as equivalent to whole breast irradiation in terms of cosmetic outcomes and satisfaction. The results suggest that PBI may be a viable option for patients seeking to minimize radiation time commitment and healthcare costs.
A Phase III trial comparing SBRT and conventional RT found no significant difference in pain response or adverse events between the treatments. The study suggests that a single fraction of 8 Gy EBRT may remain the standard of care for patients with localized spine metastases.
The NRG-GOG 0258 trial showed that carboplatin and paclitaxel chemotherapy alone resulted in comparable recurrence-free survival rates compared to combined modality treatment. The study found a reduced incidence of vaginal, pelvic, and para-aortic lymph node recurrences but increased distant recurrences with combined modality treatment.
The NRG GOG 0261 clinical trial shows that paclitaxel plus carboplatin is not inferior to paclitaxel plus ifosfamide in treating women with stage I-IV, recurrent carcinosarcoma of the uterus or ovary. The treatment improved overall survival and progression-free survival outcomes.
The study found that partial breast irradiation (PBI) is more convenient than whole breast irradiation (WBI) for women with breast cancer who do not receive adjuvant chemotherapy. PBI participants reported less fatigue and were rated more convenient, but experienced slightly poorer cosmesis compared to WBI.
A recent analysis of NRG Oncology/RTOG 9802 data suggests that both IDH-mutant subgroups of high-risk low-grade gliomas may benefit from the addition of PCV chemotherapy to radiotherapy. This finding is significant, as it enhances prognostic and predictive clarification of patients with low-grade glioma.
The study's primary endpoint showed that the total neoadjuvant therapy (TNT) approach was safe, associated with high rates of chemotherapy completion (>90%), but did not demonstrate a significant improvement in reducing cancer presence at surgery. Veliparib addition resulted in more side effects and reduced chemoradiation completion, y...
The NRG-LU001 trial showed that metformin was well-tolerated by patients with locally advanced non-small cell lung cancer, but did not improve progression-free survival or overall survival rates. The study found better-than-expected PFS and OS rates in both treatment arms.
NRG Oncology received $95 Million in NCI funding for six years, based on exceptional peer review scores. The organization will focus on increasing accrual, supporting young investigators, and raising awareness of clinical cancer research.
A clinical study demonstrated the safety and efficacy of high-dose stereotactic body radiotherapy (SBRT) for patients with centrally located non-small cell lung cancer. The treatment resulted in high tumor control rates, comparable to those seen in patients with peripheral tumors.
The NRG-RTOG 0214 trial found that prophylactic cranial irradiation improved disease-free survival, decreased brain metastasis rates, but did not improve overall survival in patients with locally advanced non-small cell lung cancer. This suggests PCI may prolong OS in a subgroup without primary tumor surgery.
The NRG Oncology trial suggests adding docetaxel-based chemotherapy to standard treatment should be considered for men with high-risk prostate cancer. The study found improved overall survival, disease-free survival, and reduced rates of distant metastases.
A phase III trial found hypofractionated radiotherapy (H-RT) to have similar QOL outcomes as conventional radiotherapy (C-RT) in men with low risk prostate cancer. H-RT delivers a total dose over a shorter period, reducing treatment duration and potential side effects.
A recent study published in the Journal of Clinical Oncology found that time to biochemical failure can be used as a surrogate endpoint for locally advanced prostate cancer treatment, reducing overall survival benefit by 6% compared to traditional endpoints. The analysis of NRG-RTOG 9202 clinical trial results showed significant associ...
The NRG Oncology clinical trial BR001 found that SBRT is safe for patients with 2 metastases or 3-4 metastases in specific locations, including peripheral lung and abdomen/pelvic. The study showed zero protocol-defined dose-limiting toxicities across evaluable anatomic locations.
A study by NRG Oncology found that short-term androgen-deprivation therapy (ADT) combined with radiotherapy improved overall survival for men with early stage prostate adenocarcinoma for up to 10.4 years. However, the benefits dissipated after 18 years.
Researchers found a link between higher levels of interleukin-10 (IL-10) and lower disease-free survival rates after radiotherapy. Elevated CRP levels, a marker of inflammation, were not associated with DFS.
Patient-reported outcomes from NRG-RTOG 0232 show that brachytherapy alone is the superior treatment for men with intermediate risk prostate cancer, with less toxicities. The study found significant differences in clinician and patient-reported late toxicity profiles between arms.